HRP20220708T4 - Postupci liječenja fibroida maternice i endometrioze - Google Patents
Postupci liječenja fibroida maternice i endometrioze Download PDFInfo
- Publication number
- HRP20220708T4 HRP20220708T4 HRP20220708TT HRP20220708T HRP20220708T4 HR P20220708 T4 HRP20220708 T4 HR P20220708T4 HR P20220708T T HRP20220708T T HR P20220708TT HR P20220708 T HRP20220708 T HR P20220708T HR P20220708 T4 HRP20220708 T4 HR P20220708T4
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- endometriosis
- treatment
- combination
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title claims 9
- 206010046798 Uterine leiomyoma Diseases 0.000 title claims 6
- 201000010260 leiomyoma Diseases 0.000 title claims 6
- 238000000034 method Methods 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 23
- 208000002193 Pain Diseases 0.000 claims 4
- 208000000450 Pelvic Pain Diseases 0.000 claims 3
- 208000007106 menorrhagia Diseases 0.000 claims 3
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229960001652 norethindrone acetate Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- AOMXMOCNKJTRQP-UHFFFAOYSA-N 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea Chemical compound C1=CC(NC(=O)NOC)=CC=C1C1=C(CN(C)C)C(C(=O)N(C=2N=NC(OC)=CC=2)C(=O)N2CC=3C(=CC=CC=3F)F)=C2S1 AOMXMOCNKJTRQP-UHFFFAOYSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000004483 Dyspareunia Diseases 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| US201662402034P | 2016-09-30 | 2016-09-30 | |
| US201662402055P | 2016-09-30 | 2016-09-30 | |
| US201762492839P | 2017-05-01 | 2017-05-01 | |
| US201762528409P | 2017-07-03 | 2017-07-03 | |
| EP17823018.1A EP3518933B2 (en) | 2016-09-30 | 2017-09-29 | Methods of treating uterine fibroids and endometriosis |
| PCT/EP2017/074907 WO2018060501A2 (en) | 2016-09-30 | 2017-09-29 | Methods of treating uterine fibroids and endometriosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20220708T1 HRP20220708T1 (hr) | 2022-07-22 |
| HRP20220708T4 true HRP20220708T4 (hr) | 2025-04-25 |
Family
ID=60915460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220708TT HRP20220708T4 (hr) | 2016-09-30 | 2017-09-29 | Postupci liječenja fibroida maternice i endometrioze |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11033551B2 (OSRAM) |
| EP (2) | EP4094766B1 (OSRAM) |
| JP (1) | JP7043503B2 (OSRAM) |
| CN (1) | CN110312512B (OSRAM) |
| AU (2) | AU2017336363B2 (OSRAM) |
| BR (1) | BR112019006227A2 (OSRAM) |
| CA (1) | CA3038879A1 (OSRAM) |
| CY (1) | CY1125254T1 (OSRAM) |
| DK (1) | DK3518933T4 (OSRAM) |
| ES (2) | ES3018413T3 (OSRAM) |
| FI (1) | FI3518933T4 (OSRAM) |
| HR (1) | HRP20220708T4 (OSRAM) |
| HU (2) | HUE072130T2 (OSRAM) |
| IL (2) | IL265700B2 (OSRAM) |
| LT (1) | LT3518933T (OSRAM) |
| MD (1) | MD3518933T4 (OSRAM) |
| MX (1) | MX2019003726A (OSRAM) |
| NZ (1) | NZ752916A (OSRAM) |
| PL (2) | PL3518933T5 (OSRAM) |
| PT (1) | PT3518933T (OSRAM) |
| RS (1) | RS63300B2 (OSRAM) |
| SI (1) | SI3518933T2 (OSRAM) |
| SM (1) | SMT202200254T1 (OSRAM) |
| WO (1) | WO2018060501A2 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3518933T2 (sl) | 2016-09-30 | 2025-05-30 | Sumitomo Pharma Switzerland Gmbh | Metode zdravljenja materničnih miom in endometrioze |
| WO2018060463A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Treatment of prostate cancer |
| JP7292566B2 (ja) | 2017-06-05 | 2023-06-19 | キッセイ薬品工業株式会社 | 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
| MA49256A (fr) | 2017-06-05 | 2021-05-26 | ObsEva SA | Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométriose |
| BR112020021276A2 (pt) * | 2018-04-19 | 2021-01-26 | Abbvie Inc. | métodos de tratamento de sangramento menstrual intenso |
| MA54058A (fr) | 2018-10-29 | 2021-09-08 | ObsEva SA | Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale |
| RU2711658C1 (ru) * | 2019-04-16 | 2020-01-20 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения наружного генитального эндометриоза |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| WO2021023877A2 (en) * | 2019-08-08 | 2021-02-11 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| JP2022551316A (ja) * | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| CN115175912B (zh) * | 2019-10-10 | 2025-04-11 | 住友制药瑞士有限公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 |
| CA3172074A1 (en) * | 2020-02-19 | 2021-08-26 | Aspira Women's Health Inc. | Compositions for endometriosis assessment having improved specificity |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| MX2022015003A (es) | 2020-05-29 | 2023-03-03 | Myovant Sciences Gmbh | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. |
| JP2023549196A (ja) | 2020-11-11 | 2023-11-22 | ミオバント サイエンシズ ゲーエムベーハー | レルゴリクスの投与方法 |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN117069735A (zh) * | 2022-05-10 | 2023-11-17 | 北京海美源医药科技有限公司 | 一种高效合成瑞卢戈利的方法和其应用 |
| WO2024015934A2 (en) * | 2022-07-13 | 2024-01-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of diagnostic screening and early detection of adenomyosis |
| TW202428262A (zh) * | 2022-11-09 | 2024-07-16 | 美商坦帕斯醫療公司 | 三唑酮化合物及其用途 |
| WO2025106820A1 (en) * | 2023-11-16 | 2025-05-22 | University Of South Florida | Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub) |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US492839A (en) | 1893-03-07 | Key for brake-shoes | ||
| US402034A (en) | 1889-04-23 | Dumping-wagon | ||
| US528409A (en) | 1894-10-30 | Denis ahern | ||
| US402055A (en) | 1889-04-23 | Water-motor | ||
| US402150A (en) | 1889-04-30 | Broadcast seed-sower | ||
| FR2512732A1 (fr) | 1981-09-14 | 1983-03-18 | Raffinage Cie Francaise | Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications |
| US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| ECSP961635A (es) | 1996-01-11 | 1997-06-27 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| ECSP971998A (es) | 1997-01-15 | 1998-04-07 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| DE19815060A1 (de) | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
| US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| US6297379B1 (en) | 1999-03-24 | 2001-10-02 | Takeda Chemical Industries, Ltd. | Thienopyrimidine compounds, their production and use |
| US6849738B2 (en) | 2000-02-29 | 2005-02-01 | Takeda Chemical Industries, Ltd. | Processes for the production of thienopyrimidine derivatives |
| US7569570B2 (en) | 2002-01-30 | 2009-08-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidines, process for preparing the same and use thereof |
| CN101153042A (zh) | 2003-01-29 | 2008-04-02 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
| ES2314448T3 (es) | 2003-07-07 | 2009-03-16 | Neurocrine Biosciences, Inc. | Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de la gonadotropina. |
| MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| US20090048273A1 (en) | 2005-07-22 | 2009-02-19 | Takeda Pharmaceutical Company Limited | Premature ovulation preventive agent |
| TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
| EA017029B1 (ru) | 2007-04-06 | 2012-09-28 | Ньюрокрайн Байосайенсиз, Инк. | Антагонисты рецептора гонадотропин-рилизинг-фактора и способы их применения |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| JPWO2010026993A1 (ja) | 2008-09-03 | 2012-02-02 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| SG186333A1 (en) | 2010-06-16 | 2013-01-30 | Endorech Inc | Methods of treating or preventing estrogen-related diseases |
| JP2012077020A (ja) | 2010-09-30 | 2012-04-19 | Mochida Pharmaceut Co Ltd | ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬 |
| RS58703B1 (sr) | 2012-09-28 | 2019-06-28 | Takeda Pharmaceuticals Co | Metoda proizvodnje derivata tienopirimidina |
| IL241595B2 (en) * | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| JP6730978B2 (ja) | 2015-02-26 | 2020-07-29 | 武田薬品工業株式会社 | 固形製剤 |
| HK1258062A1 (zh) | 2015-09-01 | 2019-11-01 | Abbvie Inc. | 给予恶拉戈利的方法 |
| SI3518933T2 (sl) | 2016-09-30 | 2025-05-30 | Sumitomo Pharma Switzerland Gmbh | Metode zdravljenja materničnih miom in endometrioze |
| WO2018060463A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Treatment of prostate cancer |
| MA49256A (fr) | 2017-06-05 | 2021-05-26 | ObsEva SA | Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométriose |
| CN115175912B (zh) | 2019-10-10 | 2025-04-11 | 住友制药瑞士有限公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| MX2022015003A (es) | 2020-05-29 | 2023-03-03 | Myovant Sciences Gmbh | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. |
| JP2023549196A (ja) | 2020-11-11 | 2023-11-22 | ミオバント サイエンシズ ゲーエムベーハー | レルゴリクスの投与方法 |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
-
2017
- 2017-09-29 SI SI201731123T patent/SI3518933T2/sl unknown
- 2017-09-29 PL PL17823018.1T patent/PL3518933T5/pl unknown
- 2017-09-29 HU HUE22162349A patent/HUE072130T2/hu unknown
- 2017-09-29 HU HUE17823018A patent/HUE059101T2/hu unknown
- 2017-09-29 MD MDE20190880T patent/MD3518933T4/ro unknown
- 2017-09-29 MX MX2019003726A patent/MX2019003726A/es unknown
- 2017-09-29 JP JP2019538721A patent/JP7043503B2/ja active Active
- 2017-09-29 CN CN201780072987.XA patent/CN110312512B/zh active Active
- 2017-09-29 AU AU2017336363A patent/AU2017336363B2/en active Active
- 2017-09-29 PT PT178230181T patent/PT3518933T/pt unknown
- 2017-09-29 ES ES22162349T patent/ES3018413T3/es active Active
- 2017-09-29 EP EP22162349.9A patent/EP4094766B1/en active Active
- 2017-09-29 NZ NZ752916A patent/NZ752916A/en unknown
- 2017-09-29 SM SM20220254T patent/SMT202200254T1/it unknown
- 2017-09-29 LT LTEPPCT/EP2017/074907T patent/LT3518933T/lt unknown
- 2017-09-29 CA CA3038879A patent/CA3038879A1/en active Pending
- 2017-09-29 DK DK17823018.1T patent/DK3518933T4/da active
- 2017-09-29 WO PCT/EP2017/074907 patent/WO2018060501A2/en not_active Ceased
- 2017-09-29 EP EP17823018.1A patent/EP3518933B2/en active Active
- 2017-09-29 HR HRP20220708TT patent/HRP20220708T4/hr unknown
- 2017-09-29 ES ES17823018T patent/ES2912929T5/es active Active
- 2017-09-29 PL PL22162349.9T patent/PL4094766T3/pl unknown
- 2017-09-29 BR BR112019006227-0A patent/BR112019006227A2/pt unknown
- 2017-09-29 FI FIEP17823018.1T patent/FI3518933T4/fi active
- 2017-09-29 RS RS20220565A patent/RS63300B2/sr unknown
-
2019
- 2019-03-28 IL IL265700A patent/IL265700B2/en unknown
- 2019-03-29 US US16/370,299 patent/US11033551B2/en active Active
-
2021
- 2021-05-11 US US17/317,769 patent/US11793812B2/en active Active
-
2022
- 2022-06-02 CY CY20221100390T patent/CY1125254T1/el unknown
- 2022-07-15 US US17/866,201 patent/US11957684B2/en active Active
- 2022-09-30 AU AU2022241582A patent/AU2022241582C1/en active Active
-
2023
- 2023-02-12 IL IL300580A patent/IL300580B2/en unknown
-
2024
- 2024-01-30 US US18/427,579 patent/US20240165118A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220708T4 (hr) | Postupci liječenja fibroida maternice i endometrioze | |
| FI3634419T3 (fi) | Gonadotropiinia vapauttavan hormonin antagonistin käsittävä annostusohjelma kohdun myoomien hoitamiseksi ja kuukautisten aiheuttaman verenhukan vähentämiseksi | |
| JP2012502988A (ja) | 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法 | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| HRP20250480T1 (hr) | Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća | |
| WO2018060463A3 (en) | Treatment of prostate cancer | |
| RS51961B (sr) | Primena flibanserina za lečenje poremećaja seksualne želje u premenopauzi | |
| HRP20210223T1 (hr) | Spojevi za promicanje rasta kose i/ili sprječavanje ili odgađanje gubitka kose kod ljudi i pripravci za takve uporabe | |
| JP2017533972A5 (OSRAM) | ||
| MY209220A (en) | Dosing regimen for the treatment of pi3k related disorders | |
| JP2009532438A5 (OSRAM) | ||
| CA2985383C (en) | Compositions for treatment of atrophic vaginitis, peri-and post-menopausal dyspareunia, and/or oophorectomized females and treatment methods therewith | |
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju | |
| MX388825B (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| JP2014523322A5 (ja) | 再調製方法 | |
| EP4580631A1 (en) | Dosage regimens of estrogen receptor degraders | |
| CA2582530A1 (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| RU2017140078A (ru) | Косметический способ и его терапевтическое применение для уменьшения объема жировой ткани | |
| FI3648761T3 (fi) | Telmisartaani kissan hypertension ehkäisemiseksi tai hoitamiseksi | |
| JP2006517557A5 (OSRAM) | ||
| AR109759A1 (es) | Métodos para tratar fibroides uterinos y endometriosis y uso | |
| JP6940265B2 (ja) | 止瀉剤組成物 | |
| Taylor et al. | P208 Effect of coadministration of etrasimod on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive | |
| CN103635194A (zh) | 用于治疗早泄的药物组合物以及用于治疗早泄的方法 | |
| WO2024206147A1 (en) | Dosage regimens of estrogen receptor degraders |